An aggressive hematolymphoid neoplasm with homozygous SMARCB1 loss shows response to EZH2 inhibition.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-06-26 DOI:10.3324/haematol.2024.285776

Iman Sarami,Amy S Duffield,Suchitra Sundaram,Douglas I Lin,Christian Salib,Shafinaz Hussein,Siraj El Jamal,Nasrin Ghesani,Busra Cangut,Bruce E Petersen

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

纯合子SMARCB1缺失的侵袭性血淋巴肿瘤对EZH2抑制有反应。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.